Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director · CEO | February 05, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date February 05, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 · Expires 2036-02-03 | Direct | 4,800,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 4,800,000 · Balance 4,800,000 F1: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 21:50 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock option (right to buy) · Derivative | 4,800,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001193125-26-039564 · ownership.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,800,000 Underlying: Common Stock · 4,800,000 shares Expires 2036-02-03 F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 4,800,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0000950170-25-112077 · ownership.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO & EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,800,000 Underlying: Common Stock · 4,800,000 shares Expires 2035-08-26 F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan"). F2 · shares: The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder. F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 35,700 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000950170-24-084295 · ownership.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO & EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,700 Underlying: Common Stock · 35,700 shares Expires 2034-07-15 F1 · security: Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:40 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 434,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0000950170-24-019430 · ownership.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO & EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,000 Underlying: Common Stock · 434,000 shares Expires 2034-02-21 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| November 29, 2023 Filed Nov 30, 2023 13:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | PurchaseCommon Stock | 11,000 | $0.89 | $9,841.70 |
DisclosureSEC source: 0000950170-23-066901 · ownership.xml · nonDerivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,001 F1 · kind: Represents 11,000 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), acquired by the reporting person in an open market transaction. F2 · balance_after: Includes 1,000 shares of Common Stock held jointly by the reporting person and the reporting person's spouse. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:28 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 525,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-23-006910 · rdgdoc.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2033-03-14 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 14:18 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherWarrants · Derivative | 9,968 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001437749-23-005165 · rdgdoc.xml · derivative · entry 2 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,968 Underlying: Common Stock · 9,968 shares Expires 2026-10-20 F2 · kind: The Reporting Person received 9,968 warrants as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. F2 · price: The Reporting Person received 9,968 warrants as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 14:18 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherWarrants · Derivative | 208,600 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001437749-23-005165 · rdgdoc.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Via Big Cypress Holdings LLC Disclosed balance after: 0 Underlying: Common Stock · 208,600 shares Expires 2026-10-20 F1 · kind: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution received 9,968 warrants of the issuer, which the Reporting Person previously had an indirect pecuniary interest. F1 · price: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution received 9,968 warrants of the issuer, which the Reporting Person previously had an indirect pecuniary interest. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 21:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 525,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-050106 · doc4.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2032-09-13 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:45 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherCommon Stock | 207,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031398 · doc4.xml · nonDerivative · entry 2 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,001 F2 · kind: The Reporting Person received 207,001 shares as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. F2 · price: The Reporting Person received 207,001 shares as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:45 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherCommon Stock | 2,500,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031398 · doc4.xml · nonDerivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Via Big Cypress Holdings LLC Disclosed balance after: 547,698 F1 · kind: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution will receive 207,001 shares of the issuer, which the Reporting Person previously had an indirect pecuniary interest. F1 · price: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution will receive 207,001 shares of the issuer, which the Reporting Person previously had an indirect pecuniary interest. Read SEC document |
| March 16, 2022 Filed Mar 19, 2022 01:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-22-011663 · doc4.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-03-16 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:05 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001493152-21-029370 · ownership.xml · derivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-11-17 F1 · shares: Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a three-year period, vesting 1/3 on the one-year anniversary of the date of grant, and the remaining 2/3 vesting pro rata on a monthly basis in 24 equal installments thereafter. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 14:48 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 1,000 | $10.11 | $10,110.00 |
DisclosureSEC source: 0001493152-21-025508 · ownership.xml · nonDerivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO and CFO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: Represents 1,000 shares of the issuer's common stock acquired jointly by the reporting person and the reporting person's spouse in open market transactions. F1 · ownership.direct: Represents 1,000 shares of the issuer's common stock acquired jointly by the reporting person and the reporting person's spouse in open market transactions. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 18:33 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 417,200 | $10.00 | $4,172,000.00 |
DisclosureSEC source: 0001493152-21-001030 · ownership.xml · nonDerivative · entry 1 Reich Samuel J · CIK 0001394645 · Director · CEO and CFO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Via Big Cypress Holdings LLC Disclosed balance after: 3,047,825 F1 · kind: The reported shares are included within the 417,200 private placement units of the issuer purchased by Big Cypress Holdings LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. The securities are held directly by the Sponsor and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.